Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans
- Susanne Lerche1,
- Birgitte Brock1,
- Jørgen Rungby1,
- Hans E. Bøtker2,
- Niels Møller3,
- Anders Rodell4,
- Bo Martin Bibby5,
- Jens J. Holst6,
- Ole Schmitz1 and
- Albert Gjedde4
- 1Institute of Pharmacology, University of Aarhus, Aarhus, Denmark
- 2Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
- 3Department of Endocrinology M, Aarhus University Hospital, Aarhus, Denmark
- 4PET-Center, Aarhus University Hospital, Aarhus, Denmark
- 5Department of Biostatistics, University of Aarhus, Aarhus, Denmark
- 6Department of Medical Physiology, University of Copenhagen, Panum Institute, Copenhagen, Denmark
- Address correspondence and reprint requests to Susanne Lerche, MD, Institute of Pharmacology, University of Aarhus, The Bartholin Building, University Park 1240, 8000 Aarhus C, Denmark. E-mail: lerche{at}ki.au.dk
Abstract
OBJECTIVE— Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents suggests a protective effect of GLP-1 on brain tissue. The mechanism is unknown. We therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption.
RESEARCH DESIGN AND METHODS— We studied 10 healthy men in a randomized, double-blinded, placebo-controlled cross-over experiment. We used positron emission tomography to determine the acute insulin-independent effect of GLP-1 on unidirectional glucose transport into the brain during a pituitary-pancreatic normoglycemic (plasma glucose ∼4.5 mmol/l) clamp with 18-fluoro-deoxy-glucose as tracer.
RESULTS— On average, GLP-1 reduced cerebral glucose transport by 27% in total cerebral gray matter (P = 0.05) and by 25–30% in individual gray matter regions (P = 0.02–0.06). The same regions revealed a uniform trend toward similarly reduced cerebral glucose metabolism. Consequently, the intracerebral glucose concentration remained constant in all regions, with and without GLP-1.
CONCLUSIONS— We have demonstrated that a hormone involved in postprandial glucose regulation also limits glucose delivery to brain tissue and hence provides a possible regulatory mechanism for the link between plasma glucose and brain glucose. Because GLP-1 reduces glucose uptake across the intact blood-brain barrier at normal glycemia, GLP-1 may also protect the brain by limiting intracerebral glucose fluctuation when plasma glucose is increased.
- BBB, blood-brain barrier
- FDG, 18-fluoro-deoxy-glucose
- GLP-1, glucagon-like peptide 1
- GLP-1R, GLP-1 receptor
- PET, positron emission tomography
- rGLP-1, recombinant GLP-1
Footnotes
-
Published ahead of print at http://diabetes.diabetesjournals.org on 8 November 2007. DOI: 10.2337/db07-1162. Clinical trial reg. no. NCT00256256, clinicaltrials.gov.
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted November 3, 2007.
- Received August 16, 2007.
- DIABETES











